When compared to conventional treatment, BMS results in more substantial and durable weight loss while improving inflammatory markers, insulin sensitivity (HOMA-IR) and resolving other underlying disease processes, including metabolic syndrome, T2DM, glycosylated haemoglobin (HbA1c), NASH, aromatase activity, visceral obesity, hypoxia and OSA [23,31,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98]. The gene discussed is CYP19A1; the disease is metabolic dysfunction-associated steatohepatitis.